227 related articles for article (PubMed ID: 19374895)
1. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
Kioulafa M; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2009 Jul; 42(10-11):970-5. PubMed ID: 19374895
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
3. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue.
Yan PS; Venkataramu C; Ibrahim A; Liu JC; Shen RZ; Diaz NM; Centeno B; Weber F; Leu YW; Shapiro CL; Eng C; Yeatman TJ; Huang TH
Clin Cancer Res; 2006 Nov; 12(22):6626-36. PubMed ID: 17121881
[TBL] [Abstract][Full Text] [Related]
4. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
7. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
8. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M; Balkouranidou I; Sotiropoulou G; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Int J Cancer; 2009 Dec; 125(12):2887-92. PubMed ID: 19551853
[TBL] [Abstract][Full Text] [Related]
9. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B
Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661
[TBL] [Abstract][Full Text] [Related]
10. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women.
Li Y; Wei Q; Cao F; Cao X
Oncol Rep; 2008 May; 19(5):1149-53. PubMed ID: 18425370
[TBL] [Abstract][Full Text] [Related]
11. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
Lewis CM; Cler LR; Bu DW; Zöchbauer-Müller S; Milchgrub S; Naftalis EZ; Leitch AM; Minna JD; Euhus DM
Clin Cancer Res; 2005 Jan; 11(1):166-72. PubMed ID: 15671542
[TBL] [Abstract][Full Text] [Related]
14. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
16. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
18. Role of physical activity in modulating breast cancer risk as defined by APC and RASSF1A promoter hypermethylation in nonmalignant breast tissue.
Coyle YM; Xie XJ; Lewis CM; Bu D; Milchgrub S; Euhus DM
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):192-6. PubMed ID: 17301249
[TBL] [Abstract][Full Text] [Related]
19. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
